Andrew Wotherspoon

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

Ian Chau, David Cunningham, David González et al. · The Lancet Oncology · 2013 · 723 citations · Full text

Oncology, Open-label Phase 3, Cancer Management +7

Mismatch Repair Deficiency, Microsatellite Instability, and Survival

Elizabeth Smyth, Andrew Wotherspoon, Clare Peckitt et al. · JAMA Oncology · 2017 · 509 citations · Full text

Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer

Ian Chau, Gina Brown, David Cunningham et al. · Journal of Clinical Oncology · 2006 · 477 citations · Full text

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

Frederick Arce Vargas, Andrew J.S. Furness, Isabelle Solomon et al. · Immunity · 2017 · 425 citations · Full text

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

Sophia Frentzas, Ève Simoneau, Victoria L. Bridgeman et al. · Nature Medicine · 2016 · 423 citations

Angiogenesis, Hepatology, Medicine +12